Clinical Trial Update: Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the combination of sunitinib and temsirolimus in renal cell carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)
• Torisel (Temsirolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Cancer, Kidney Cancer | Phase 1 | Status: COMPLETED